menu
    • menu
    [{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Lu AG13909","moa":"ACTH receptor","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lu AG13909","moa":"ACTH receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lu AF82422","moa":"Alpha-synuclein","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lu AF82422","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lu AF82422","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Lu AF82422","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Lu AF20513","moa":"Beta-amyloid","graph1":"Neurology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Lu AF20513","moa":"Beta-amyloid","graph1":"Neurology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Lu AF20513","moa":"Beta-amyloid","graph1":"Neurology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Orsini Specialty Pharmacy","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2020","type":"Agreement","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Orsini Specialty Pharmacy","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Orsini Specialty Pharmacy"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Alder Biopharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ Alder Biopharmaceuticals Inc","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Alder Biopharmaceuticals Inc"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ubrogepant","moa":"Calcitonin gene-related peptide type 1 receptor","graph1":"Neurology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Alder Biopharmaceuticals Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ALD1910","moa":"CGRP","graph1":"Neurology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Alder Biopharmaceuticals Inc","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Alder Biopharmaceuticals Inc"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Aripiprazole Va","moa":"D2\/5-HT1A\/5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Bendamustine Hydrochloride","moa":"DNA","graph1":"Oncology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lu AF28996","moa":"Dopamine D1 receptor (D1R)","graph1":"Neurology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lu AF28996","moa":"Dopamine D1 receptor (D1R)","graph1":"Neurology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lu AF28996","moa":"Dopamine D1 receptor (D1R)","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lu AF28996","moa":"Dopamine D1 receptor (D1R)","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lu AF28996","moa":"Dopamine D1 receptor (D1R)","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Lu AF35700","moa":"Dopamine D2 receptor (D2R)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Lu AF35700","moa":"Dopamine D2 receptor (D2R)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Lu AF35700","moa":"Dopamine D2 receptor (D2R)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Lu AF35700","moa":"Dopamine D2 receptor (D2R)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Lu AF35700","moa":"Dopamine D2 receptor (D2R)","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Lu AF35700","moa":"Dopamine D2 receptor (D2R)","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Lu AF35700","moa":"Dopamine D2 receptor (D2R)","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Lu AF35700","moa":"Dopamine D2 receptor (D2R)","graph1":"Nephrology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Lu AF35700","moa":"Dopamine D2 receptor (D2R)","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Lu AF35700","moa":"Dopamine D2 receptor (D2R)","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Lu AF35700","moa":"Dopamine D2 receptor (D2R)","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"||Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Sleep","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka America Pharmaceutical, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor||Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor | Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"H. Lundbeck AS \/ Otsuka Holdings","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Otsuka Holdings"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Flupenthixol","moa":"DRD1","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Flupenthixol","moa":"DRD1","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Flupenthixol","moa":"DRD1","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Clobazam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Clobazam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"DENMARK","productType":"Controlled Substance","year":"2010","type":"Inapplicable","leadProduct":"Clobazam","moa":"GABA-A receptor; anion channel","graph1":"Rare Diseases and Disorders","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Clobazam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Clobazam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vigabatrin","moa":"Gamma-amino-N-butyrate transaminase","graph1":"Neurology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vigabatrin","moa":"Gamma-amino-N-butyrate transaminase","graph1":"Neurology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Vigabatrin","moa":"Gamma-amino-N-butyrate transaminase","graph1":"Neurology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bexicaserin","moa":"HTR2C","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Liquid","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Longboard Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Bexicaserin","moa":"HTR2C","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":2.6000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":2.6000000000000001,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Longboard Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Bexicaserin","moa":"HTR2C","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":2.6000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":2.6000000000000001,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Foliglurax","moa":"Metabotropic glutamate receptor 4","graph1":"Neurology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Foliglurax","moa":"Metabotropic glutamate receptor 4","graph1":"Neurology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Foliglurax","moa":"Metabotropic glutamate receptor 4","graph1":"Neurology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Foliglurax","moa":"Metabotropic glutamate receptor 4","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Foliglurax","moa":"Metabotropic glutamate receptor 4","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Lu AF87908","moa":"Microtubule-associated protein tau (MAPT)","graph1":"Neurology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lu AG06466","moa":"Monoacylglycerol lipase","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lu AG06466","moa":"Monoacylglycerol lipase","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lu AG06466","moa":"Monoacylglycerol lipase","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lu AG06466","moa":"Monoacylglycerol lipase","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lu AG06466","moa":"Monoacylglycerol lipase","graph1":"Neurology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lu AG06466","moa":"Monoacylglycerol lipase","graph1":"Neurology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lu AG06466","moa":"Monoacylglycerol lipase","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Lu AG06466","moa":"Monoacylglycerol lipase","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lu AG06466","moa":"Monoacylglycerol lipase","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lu AG06466","moa":"Monoacylglycerol lipase","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lu AG06466","moa":"Monoacylglycerol lipase","graph1":"Neurology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ITALY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Rasagiline Mesylate","moa":"Monoamine oxidase B","graph1":"Neurology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu opioid receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"OPRM1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"OPRM1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Nalmefene Hydrochloride","moa":"OPRM1","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lu AG09222","moa":"PACAP38","graph1":"Neurology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Lu AG09222","moa":"PACAP38","graph1":"Neurology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Lu AG09222","moa":"PACAP38","graph1":"Neurology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Lu AG09222","moa":"PACAP38","graph1":"Neurology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lu AG09222","moa":"PACAP38","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Lu AG09222","moa":"PACAP38","graph1":"Immunology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Lu AF76432","moa":"PDE1","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Lu AF11167","moa":"Phosphodiesterase 10A (PDE10)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Lu AF11167","moa":"Phosphodiesterase 10A (PDE10)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lu AF11167","moa":"Phosphodiesterase 10A (PDE10)","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lu AF11167","moa":"Phosphodiesterase 10A (PDE10)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lu AF11167","moa":"Phosphodiesterase 10A (PDE10)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Lu AF11167","moa":"Phosphodiesterase 10A (PDE10)","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lu AF11167","moa":"Phosphodiesterase 10A (PDE10)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Difamilast","moa":"Phosphodiesterase 4","graph1":"Dermatology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Enzyme","year":"2010","type":"Inapplicable","leadProduct":"Desmoteplase","moa":"Plasminogen","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Risperidone","moa":"Serotonin 2a (5-HT2a) receptor | Dopamine D2 receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Icon Plc","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Icon Plc"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Idalopirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Idalopirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Idalopirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Idalopirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Idalopirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Idalopirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Idalopirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Idalopirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Idalopirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Idalopirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Denovo Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Idalopirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Denovo Biopharma","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Denovo Biopharma"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Idalopirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Idalopirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Idalopirdine","moa":"Serotonin 6 (5-HT6) receptor","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"1","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Amlenetug","moa":"SNCA","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Amlenetug","moa":"SNCA","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Amlenetug","moa":"SNCA","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Amlenetug","moa":"SNCA","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Ligand Pharmaceuticals | Icon Plc | Quintiles Inc","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Carbamazepine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Ligand Pharmaceuticals | Icon Plc | Quintiles Inc","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Ligand Pharmaceuticals | Icon Plc | Quintiles Inc"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Carbamazepine","moa":"Sodium channel alpha subunit","graph1":"Neurology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Zicronapine","moa":"tricyclic compounds","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Zicronapine","moa":"tricyclic compounds","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"11-C Lu AF88370","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"11-C Lu AF90103","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"11-C PXT012253","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"14-C Lu AG06466","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Ldalopirdine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Lu AE04621","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Lu AF88434","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Lu AF88434","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Lu AF90103","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Lu AF95245","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Lu AG06474","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Lu AG06474","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Lu AG06474","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Solution","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Lu AG06479","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Lu AG22515","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Lu AG22515","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"DENMARK","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"antidepressants (fluoxetine type): thioether derivatives||Undisclosed||Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Sun Pharmaceutical Industries Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"Vortioxetine Hydrobromide","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Vortioxetine Hydrobromide","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Neuro3 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Undisclosed","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Neuro3 Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"H. Lundbeck AS \/ Neuro3 Therapeutics"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"DCAI","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"DENMARK","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ DCAI","highestDevelopmentStatusID":"2","companyTruncated":"H. Lundbeck AS \/ DCAI"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"3","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Rgenta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Neurology","graph2":"Discovery Platform","graph3":"H. Lundbeck AS","amount2":0.11,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ H. Lundbeck AS","highestDevelopmentStatusID":"3","companyTruncated":"H. Lundbeck AS \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Colorado Springs Neurological Associates","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Pill","sponsorNew":"H. Lundbeck AS \/ Colorado Springs Neurological Associates","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Colorado Springs Neurological Associates"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"William Ondo, MD","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Neurology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ William Ondo, MD","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ William Ondo, MD"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Alberto Espay","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Droxidopa","moa":"Adrenergic receptor","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Alberto Espay","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Alberto Espay"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"George Medvedev","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Eptinezumab","moa":"Calcitonin gene-related peptide","graph1":"Neurology","graph2":"Approved FDF","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"H. Lundbeck AS \/ George Medvedev","highestDevelopmentStatusID":"15","companyTruncated":"H. Lundbeck AS \/ George Medvedev"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Pavel Klein","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"DENMARK","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Clobazam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Pavel Klein","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ Pavel Klein"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Markus KOSEL","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"H. Lundbeck AS \/ Markus KOSEL","highestDevelopmentStatusID":"9","companyTruncated":"H. Lundbeck AS \/ Markus KOSEL"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"William Ondo, MD","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"DENMARK","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tetrabenazine","moa":"Synaptic vesicular amine transporter","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Pill","sponsorNew":"H. Lundbeck AS \/ William Ondo, MD","highestDevelopmentStatusID":"11","companyTruncated":"H. Lundbeck AS \/ William Ondo, MD"}]

    Find Clinical Drug Pipeline Developments & Deals by H. Lundbeck AS

    Menu

    H. Lundbeck AS

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lu AG09222

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lundbeck Expands Lu AG09222 Migraine Trial to Include IV Dose Arm

                            Details : Lundbeck is developing Lu AG09222, an investigational monoclonal antibody (mAb) with an innovative mode of action, designed to bind and inhibit pituitary adenylate cyclase-activating polypeptide.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 31, 2025

                            Lead Product(s) : Lu AG09222

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brexpiprazole

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rxulti® Approved in EU for Treating Schizophrenia in Adolescents

                            Details : Rxulti (brexpiprazole) is an atypical antipsychotic, small molecule drug candidate. It is indicated for the treatment of schizophrenia in adolescents aged 13 years and older.

                            Product Name : Rxulti

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 17, 2025

                            Lead Product(s) : Brexpiprazole

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amlenetug

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lundbeck's MSA Treatment Gains Orphan Drug Status in Japan

                            Details : Lu AF82422 (amlenetug) is a alpha-synuclein binder, antibody candidate, which is currently being evaluated for the treatment of multiple system atrophy.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 10, 2025

                            Lead Product(s) : Amlenetug

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amlenetug

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lundbeck's Amlenetug Gets FDA Fast Track for Multiple System Atrophy

                            Details : Lu AF82422 (amlenetug) is a alpha-synuclein binder, antibody candidate, which is currently being evaluated for the treatment of multiple system atrophy.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 12, 2025

                            Lead Product(s) : Amlenetug

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amlenetug

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lundbeck Starts Phase 3 Amlenetug Study in Multiple System Atrophy

                            Details : Lu AF82422 (amlenetug) is a human mAb that binds to extracellular α-synuclein and prevents the uptake and inhibit seeding of aggregation in patients with multiple system atrophy.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 27, 2024

                            Lead Product(s) : Amlenetug

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eptinezumab

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

                            Details : Eptinezumab is a Antibody drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Migraine Disorders.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 22, 2024

                            Lead Product(s) : Eptinezumab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Recipient : Charles River Laboratories, Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Charles River and Lundbeck Use AI To Discover Neurological Disease Drugs

                            Details : The agreement aims to advance the discovery of novel drugs for neurological disease by utilizing Logica which translates biological insights into optimized preclinical candidates.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 02, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Recipient : Charles River Laboratories, Inc

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ubrogepant

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine

                            Details : Ubrogepant is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Migraine Disorders.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 29, 2024

                            Lead Product(s) : Ubrogepant

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lu AG22515

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease

                            Details : Lu AG22515 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Graves Ophthalmopathy.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            August 16, 2024

                            Lead Product(s) : Lu AG22515

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            H. Lundbeck AS

                            Denmark arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Recipient : Otsuka Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Otsuka and Lundbeck Announce FDA Acceptance for Brexpiprazole in PTSD Treatment

                            Details : Rexulti (brexpiprazole) is an partial agonist of serotonin 5-HT1A, which is being investigated in combination therapy with sertraline for the treatment of post-traumatic stress disorder (PTSD).

                            Product Name : Rexulti

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 25, 2024

                            Lead Product(s) : Brexpiprazole,Sertraline Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Recipient : Otsuka Pharmaceutical

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth